Imfinzi (durvalumab)

Impact of TMB, PD-L1 , genomic features, and pneumonitis on CRT and durvalumab response in stage III NSCLC – @alessi_joao #MemorialSloanKetteringCancer #cancer #danafarber #durvalumab #pneumonitis #oncology #oncodaily https://t.co/CQD3cZyn5m (@oncodaily)

🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC. Out in @NatureComms our multi-center analysis led by🌟 @alessi_joao. #biomarkers can help⬆️outcomes. @OncoAlert #LCSM (@BiagioRicciutMD)

#Italian real-world evidence of #durvalumab, gemcitabine, cisplatin in advanced #biliarytractcancer #cholangiocarcinoma #CCA #BTC ⁦@LiverInt⁩ ⁦@casadei_gardini⁩ ⁦@lonardi_sara⁩ ⁦@Mom_enji⁩ ⁦@HUNIMED⁩ ⁦@HumanitasMilano⁩ https://t.co/ENsCg2QXMK (@LorenzaRimassa)

Our last paper—> Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data @LorenzaRimassa @sara_lonardi1 @Mom_enji @fedenichetti https://t.co/5aHbvCT7Bd (@casadei_gardini)

Check out Dr. Benjamin Besse @BenjaminBesseMD @GustaveRoussy discussing #ASCO23 LATIFY -Ceralasertib + Durvalumab vs. Docetaxel in pts w/ Locally Advanced or Met. #NSCLC That Progressed on or After Anti-PD-(L)1 & Platinum-Based Tx #LCSM #lungcancer @EORTC https://t.co/7lk52kCdH5 (@Sameh_VuMedi)

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://t.co/4dphxuN1s4 cc: @BladderCancerUS @JCensits @PGrivasMDPhD (@eaonc)

13/15 #TumorBoardTuesday What about DatoDXd in localized TNBC? ✨TROPION-Breast03 Phase 3 Dato-DXd +/- durvalumab in pts with residual TNBC after neoadj Rx ➡️Control: capecitabine +/- pembrolizumab 🔮Looking forward to results comparing adj ADCs to SOC! 📚https://t.co/lmZxMfMj03 (@ArielleMedford)

12/15 #TumorBoardTuesday #BCSM 📌Other ADCs target Trop2 ✨BEGONIA✨ DatoDXd + durvalumab in 29 pts w/mTNBC ➡️74% response - 7% complete, 67% partial 📚#PeterSchmid https://t.co/hLYGlnh4CT (@ArielleMedford)

@DanengLi, MD, discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab. What are your thoughts on this case? #gicsm | @cityofhope https://t.co/ibhA0HJtfT https://t.co/L860Tf97dX (@TargetedOnc)

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://t.co/4dphxuN1s4 cc: @BladderCancerUS @JCensits @PGrivasMDPhD (@eaonc)

EA8192, led by @JCensits and @PGrivasMDPhD, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: https://t.co/4dphxuN1s4 #blcsm (@eaonc)

4-years OS update from HIMALAYA ph-3 trial in unresectable hepatocellular carcinoma. STRIDE regimen (Tremelimumab + Durvalumab) maintains significant long-term OS benefit vs sorafenib. At 4 years, 1/4 of the patients in the STRIDE arm remained alive. Very good results! #WCGIC2023 (@carlosbon78)

4-yr OS update from the phs 3 HIMALAYA trial of tremelimumab + durvalumab in HCC at #WCGIC2023 👉Excellent long-term survival data for STRIDE 👉4-yr OS rate of 19% (unprecedented in HCC) 👉Long-term OS observed in relevant subgroups, incl. pts with non-viral liver disease… https://t.co/ZTzq8PM6je (@ArndtVogel)

What do we know about resistance to durvalumab post chemoradiation (PACIFIC) for NSCLC? Report @JTOonline associates CD73 expression and low CD8+ TIL density with poor outcomes. Support for oleclumab? Paired biopsies show role of neoantigen plasticity. https://t.co/1yYvtvjUEV (@StephenVLiu)

#Clinicaltrial EA8192 aims to find out if treatment with durvalumab and chemotherapy can improve outcomes for patients with high grade upper tract #urothelialcancer prior to nephroureterectomy. https://t.co/4dphxuN1s4 #blcsm #bladdercancer cc: @JCensits, @PGrivasMDPhD (@eaonc)

Antibiotics can be administered without compromising treatment efficacy in patients receiving a durvalumab-based regimen for advanced biliary tract #cancer. @ASCO @RuthHe12 @LombardiCancer https://t.co/vkM4mqsKf0 (@gastroendonews)

Very pleased to share the results of our study on the impact of radiation to host immune structures in patient treated with CCRT and durvalumab in LA NSCLC. Small homogeneous population but very interesting results! ⬇️ Thanks @jnt_khalifa for the help on this project! (@Cocopasq)

Narjust Florez, MD, and Filippo Gustavo Dall’Olio, MD, on NSCLC: New Findings on Tumor Fraction, Durvalumab, and Survival https://t.co/R1kWOPUEm6 #LCSM #lungcancer #oncology @NarjustFlorezMD @DanaFarber @DanaFarberNews (@ASCOPost)

Retrospective look at pneumonitis with the PACIFIC regimen for unresectable NSCLC in #JTOCRR. In 78 pts treated with ≥60 Gy CRT followed by durvalumab, 28% pneumonitis rate: 1% G1, 10% G2, 8% G3, no G4, 9% G5. @JTOonline https://t.co/PbOiY7GLfh (@StephenVLiu)

Urothelial cancer is the most common type of #bladdercancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://t.co/4dphxuN1s4 cc: @BladderCancerUS @JCensits @PGrivasMDPhD (@eaonc)

My answer would be no. I dont think we have enough data but retrospective evidence suggests patients EGFR-mutated NSCLC do not benefit with consolidation durvalumab and experienced a high frequency of irAEs. https://t.co/Pa5skwPQe8 (@TkarawadiaMD)

Durvalumab + standard neoadjuvant chemotherapy significantly improved pCR over neoadjuvant chemotherapy alone in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. @TaberneroJosep @vallhebron #oncology https://t.co/lLL881F9ww (@OncLive)

Durvalumab + standard neoadjuvant chemotherapy significantly improved pCR over neoadjuvant chemotherapy alone in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers. @TaberneroJosep @vallhebron #oncology https://t.co/oL2KDdDDzY (@OncLive)

Neoadjuvant Durvalumab Plus Chemo Improves pCR Vs Chemo Alone in Gastric and GEJ Cancers @TaberneroJosep @vallhebron #oncology https://t.co/A7HnUd9X3R (@OncLive)

New #JITC article: Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study https://t.co/HGnmbOlaQa @OmidHamidMD @jmkirkwood @PAscierto (@jitcancer)

EA8192, led by @JCensits and @PGrivasMDPhD, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: https://t.co/4dphxuN1s4 #blcsm (@eaonc)

Activity of cabozantinib + durvalumab in patients with advanced #UrothelialCarcinoma or non-UC variant histologies after platinum chemotherapy: iterim results from the phase 2 #ARCADIA trial - @giannatempopatr @IstTumori. #ASCO23 > https://t.co/4NJz0PKEPf @tchandra_uromd (@urotoday)

TPS8609: Phase 3 trial of durvalumab combined with domvanalimab (AB154, anti-TIGIT) following concurrent chemoradiotherapy in patients with unresectable stage III NSCLC (PACIFIC-8, NCT05211895) by @AlexSpiraMDPhD. #ASCO23 #LCSM (@HHorinouchi)

Results show that durvalumab plus olaparib added to standard care improves PFS in newly diagnosed advanced #ovariancancer w/out BRCA mutation. Findings were introduced in an #ASCO23 news briefing. @DrMarkham of @UFMedicine shares insights. #onctwitter https://t.co/sfEx1ErEbz (@OBRtweets)

Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. @UPMCnews @UPMCHillmanCC @AnwaarSaeed3 & colleagues @CellRepMed #ASCO23 https://t.co/Px2ISHF1ec (@CellPressNews)

@ILSONDavid discussant on adj #IO to chemo and #IO to periop chemo in resectable gastric/GEJ cancer, benefit appears to be driven by #PD-L1 status, notes MATTERHORN press release also met primary endpoint of pCR rate (periop chemo + durvalumab) #ASCO23 @OncoAlert (@jgong15)

#ASCO23 @Oncoalert 📚UNICANCER SAFIR02-Lung explores ctDNA in NSCLC pts on durvalumab maintenance post-chemo 🔬 16% pts Tumor Fraction (TF) ≥2% 👥 Lower PFS (1.7m vs 5.8m) & OS (10.4m vs 25.9m) in TF ≥2% pts ? limited benefit of durvalumab for TF+ pts @BenjaminBesseMD (@ADesaiMD)

#Clinicaltrial EA8192 aims to find out if treatment with durvalumab and chemotherapy can improve outcomes for patients with high grade upper tract #urothelialcancer prior to nephroureterectomy. https://t.co/4dphxuN1s4 #blcsm #bladdercancer cc: @JCensits, @PGrivasMDPhD (@eaonc)

A few @eaonc poster presentations in #lungcancer (current trials) Sun 6/4 1st line Durvalumab w/chemo in advanced pleural #mesothelioma @FordePatrick ECOG-ACRIN LUNG-MAP substudy: phase II - sotorasib in prev treated pts with #KRAS G12C @SukiPaddaMD #LCSM @KRASKickers #ASCO23 (@jillfeldman4)

Durvalumab + platinum-based chemotherapy, followed by maintenance therapy w/ either durvalumab + olaparib or durvalumab alone, elicited an improvement in PFS in newly diagnosed, advanced/ recurrent endometrial cancer. @ShannonWestin @MDAndersonNews #gyncsm https://t.co/WvbJWMscfQ (@OncLive)

Edward S. Kim, MD, MBA, discussed the PACIFIC and PACIFIC-R studies of #durvalumab in patients with unresectable stage III #NSCLC. #lcsm | @cityofhope @DrEdKim https://t.co/tJluMKvfTL (@TargetedOnc)

Durvalumab + platinum-based chemotherapy, followed by maintenance therapy w/ either durvalumab + olaparib or durvalumab alone, elicited an improvement in PFS in newly diagnosed, advanced/ recurrent endometrial cancer. @ShannonWestin @MDAndersonNews #gyncsm https://t.co/PCR62rkQir (@OncLive)

@ASCO is coming up next week! @MirzaCPH will present: A randomized trial of olaparib, durvalumab, and #cancervaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent #ovariancancer: ENGOT-OV56/NSGO-CTU-DOVACC trial #phase2 #immunotherapy https://t.co/9YWK7m4cHZ (@ultimovacs)

Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer https://t.co/Js2OhmTijy vía @onclive (@DrMedOnco)

🔥Durvalumab + tremelimumab for advanced neuroendocrine neoplasms of gastroenteropancreatic & lung origin @NatureComms https://t.co/pbeNroajHh 🔎Dune phs-II, 123 pts 🧐Modest survival benefit only in G3 GEP-NENs, PDL-1 not predictive @myESMO @OncoAlert @EASLedu (@ArndtVogel)

It is out in print! DUNE - durvalumab and tremelimumab in G3 neuroendocrine neoplasms. Like in similar studies, there seems to be modest efficacy but how can we better select patients? Congrats @Ja_Capdevila @JHernando3 @kimtruss @PaulaJFonseca https://t.co/GfKRtzIY7x (@OncoThor)

Durvalumab Plus Chemotherapy With or Without Olaparib Improves PFS in Advanced Endometrial Cancer @ShannonWestin @MDAndersonNews #gyncsm https://t.co/6uLrdfm4d5 (@OncLive)